Latest news with #Medical
Yahoo
2 days ago
- General
- Yahoo
Cops dramatically rescue three men left treading water in darkness after their plane crashed off Florida coast
New video shows the moment rescuers saved three men after they were left treading water when their plane crashed along Florida's Treasure Coast last weekend. Officials received a distress call at 8.24 p.m. Sunday from a single-seated Cessna 172 Skyhawk as it plunged into the waters off Vero Beach after the pilot reported engine issues. The aircraft took off from Flagler Executive Airport in Palm Coast, 150 miles to the north, just before 7 p.m. The alert sparked a multi-agency search and rescue mission. It was the Indian River County Sheriff's Office helicopter, 'Hawk,' that found the three in the water using its thermal imaging and infrared cameras. Sheriff Eric Flowers said in a press conference Monday that the helicopter pilots were unable to find any visible debris from the crash, describing the rescue mission like 'looking for a needle in a haystack' in the middle of the ocean. Instead of debris, Flowers said that helicopter pilot Deputy Jonathan Lozada eventually noticed 'three heads bobbing in the water' around 8.45 p.m. Lozada told the media that conditions were stacked against the rescue teams. 'It was very dark out there,' he said in a press conference Monday. 'Even though we have night vision goggles, we're still very limited on visibility. So for us to be able to go that far offshore, it's just unsafe for us.' Lozada said the three passengers might never have been found if more time had elapsed. At around 9:50 p.m. Sunday, officials from the Air and Marine Operations, an operational component of U.S. Customs and Border Protection, found two survivors in the water, the agency said. 'Coast Guard, Coast Guard, you have two that you're in contact with. There is one more at about your 11 o'clock. He's drifting off by himself,' one of the helicopter pilots said in a video of the rescue shared by the sheriff's office on Facebook. The third man was pulled out of the water shortly after he was spotted. Bodycam footage from an Air and Marine Operations agent showed the moment one of the survivors was assisted up to the boat using a rope. The man, who later identified himself as the pilot, stated that only three people had been on board the plane. 'We have three,' he said. 'We are three.' Flowers said that the pilot appeared to be in the worst condition and in the most distress. The man was recorded screaming as he was transferred to the Coast Guard 45-foot vessel for Emergency Medical Technician evaluation after complaining of 'severe rib pain,' according to the CBP. All three survivors were taken to Coast Guard Station Fort Pierce for further medical treatment. The sheriff's office said the victims are in stable condition. Assistant Fire Chief Steve Greer of Indian River County Fire Rescue said that the three survivors attempted to swim to shore. The National Transportation Safety Board and the Federal Aviation Administration (FAA) are investigating the cause of the crash. A preliminary crash report was expected to be available on Tuesday. The plane was headed for Vero Beach Municipal Airport and had been due to land around 8:30 p.m. local time.
India Gazette
2 days ago
- Health
- India Gazette
"38 COVID-19 cases reported in last three weeks": Andhra Pradesh Principal Secretary for Health MT Krishna Babu
Amaravathi (Andhra Pradesh) [India], June 3 (ANI): Andhra Pradesh Principal Secretary for Health, Medical, and Family Welfare, MT Krishna Babu, on Monday said that 38 COVID-19 cases have been confirmed in the state over the past three weeks. He confirmed that no new variant has been detected so far. He added that doctors are advising home isolation for most infected individuals, and the government has ensured that all hospitals are adequately prepared to handle any possible surge. Speaking to ANI, MT Krishna Babu said, 'The COVID situation is under control and we are monitoring it daily. In the last three weeks, around 38 cases have been reported. We are sending all samples for genome sequencing to check for new variants, but so far, no new strain has been found. Most patients are recovering at home with basic treatment, except in cases where other health problems make it more serious. From today, we have increased testing to around 500 people per day. All hospitals are fully prepared with the necessary infrastructure to handle any situation.' As of 8 AM on Monday, June 2, India's active COVID-19 caseload stood at 3,961, according to the Ministry of Health and Family Welfare. The cumulative COVID-19 deaths in the country since January this year have increased to 32, with four deaths reported since Sunday. According to official data, 203 new cases were added to the active case count since Sunday. Delhi, Tamil Nadu, Maharashtra, and Kerala each reported one COVID-19 death since Sunday. Delhi reported 47 more COVID-19 cases, increasing the total active cases in the national capital to 483. In Kerala, active COVID-19 cases rose to 1,435, with 35 new cases reported since Sunday. In Maharashtra, 21 new COVID-19 cases were reported, taking the active case count to 506. In West Bengal, 44 new COVID-19 cases were reported, increasing the state's active cases to 331. (ANI)
Yahoo
6 days ago
- Health
- Yahoo
An Introduction to the Design and Development of Medical Devices (Online Training Course: July 23-24, 2025) - Access Key Information on Documentation Management and Systems
Dublin, May 30, 2025 (GLOBE NEWSWIRE) -- The "An Introduction to the Design and Development of Medical Devices Training Course" training has been added to offering. This intensive two-day course will introduce those who are new to medical device design and development to the critical elements of the process. It has been designed to provide delegates with an insight into the tools and techniques required to design and develop a medical device and offer an essential overview of the current regulatory landscape. The importance of safety and efficacy will be covered, as will risk management and documentation. As combination products are a huge market, the programme will also address device constituent parts of combination products. Attending this event will provide delegates with a comprehensive appraisal of key aspects of this process and an opportunity to discuss the complexities involved with an experienced industry expert. Benefits of attending: Gain a comprehensive overview of the design and development process Comply with the regulatory requirements and standards Learn about design controls Review materials and biocompatibility Access key information on documentation management and systems Understand how risk should be managed Consider human factors and usability studies Certifications: CPD: 12 hours for your records Certificate of completion Who Should Attend? Design and development personnel Development engineers Quality personnel Regulatory personnel Design control professionals Documentation managers Programme managers Anyone who needs an overview of the medical device design and development process Agenda Day 1 Overview of the regulations and market routes Regulatory pathways Medical Device Directive (MDD) vs Medical Device Regulation (MDR) - key differences EU vs US (FDA) - markets to consider Medical device vs combination product (drug/device and device/drug) - which regulation applies? Device classification and the implications for your product Resources and sources The design and development process The stages of design and development Key considerations Terminology Intended use Project complexity Mandatory requirements Design and development tools Inspiration, innovation and determination Materials and biocompatibility DFx, Design for....? Manufacturing - key considerations Day 2 Design Control Appropriate design and development planning Translation of marketing requirements SMART design inputs Is a trace matrix appropriate? Meaningful design outputs Verification and validation Design reviews Design transfer Design history file vs technical file Change control Notified Bodies (NB) Risk management - what is required? What is risk management and when should it be applied? What does the guidance say? Help or hindrance? How to implement a practical risk management plan Tools and techniques to help you succeed Clinical evaluation, human factors and usability - how to comply Planning your clinical evaluation How to incorporate human factors and usability studies into your design and development process - MDR and FDA requirements User instructions Training considerations - when and who do you need to train? Formative studies Validation/summative studies SpeakerDavid Howlett Director, PharmaDelivery Solutions Howlett is the Director of PharmaDelivery Solutions Ltd. In 2003 he established the company as a highly specialised consultancy service in the field of drug delivery device technology. This has led to involvement in projects with focus in pulmonary, nasal and other delivery routes, with an international client base. Much of the activity of PharmaDelivery Solutions Ltd is focused in the area of development programme support, regulatory GAP analysis, establishing design control systems and design verification, planning and execution, materials strategies and type III device Drug Master Files (DMFs). PharmaDelivery Solutions Ltd has provided key programme inputs in various forms including due diligence, regulatory GAP Analysis, strategic and detailed planning, implementation, mentoring and training. In addition to activities supporting commercial organizations, has been involved in the following roles; Honorary Teaching Fellow in the School of Pharmacy and Pharmaceutical Sciences at the University of Manchester and is author/ tutor for the Pharmaceutical Industry Advanced Training (PIAT) MSc module on Inhalation dosage forms A UK national expert representing the British Standards Institute developing international standard ISO 20072:2009 for pulmonary and nasal delivery, and a committee member on other standards committees Worked with the United Nations and various national governments to develop and establish transition strategies from the use of CFC in Metered Dose Inhalers and to secure appropriate budgets from the Multi-lateral fun for the implementation of the Montreal Protocol An invited speaker at a number of international meetings and symposia on device development related subjects, including regulatory expectation, DPI development, extractables and leachables control and emerging marketsFor more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
27-05-2025
- Business
- Yahoo
Continuing Medical Education (CME) Market Report 2025: Revenues to Grow from $9.41 in 2025 to $14.6 Billion by 2030, at 9.15% CAGR
Dublin, May 27, 2025 (GLOBE NEWSWIRE) -- The "Continuing Medical Education Market - Global Forecast to 2030" report has been added to Continuing Medical Education Market grew from USD 8.63 billion in 2024 to USD 9.41 billion in 2025. It is expected to continue growing at a CAGR of 9.15%, reaching USD 14.60 billion by continuing medical education ecosystem is undergoing profound transformation fueled by technological innovation, changing learner expectations, and novel regulatory imperatives. Digital platforms now offer immersive virtual simulations and interactive webinars that rival in-person symposia for engagement and outcomes. As a result, providers are investing in adaptive learning technologies capable of tailoring content to individual competency learner preferences have shifted decisively toward flexible, on-demand formats, enabling professionals to integrate education seamlessly into busy clinical schedules. This has catalyzed a move away from multi-day conferences toward modular courses and microlearning experiences. In parallel, accreditation bodies are revising criteria to accommodate hybrid delivery models, granting credits for both digital and face-to-face agencies, meanwhile, are adopting more rigorous standards for commercial support disclosures and conflict-of-interest management, prompting providers to enhance transparency and governance frameworks. These concurrent shifts-technological, pedagogical, and regulatory-are converging to redefine excellence in continuing education, demanding that stakeholders adopt agile strategies to remain competitive and the 2025 United States Tariff Impact on CMEIn 2025, newly implemented tariffs on imported educational hardware, digital infrastructure components, and medical devices introduced additional cost layers for event organizers and content providers. Equipment such as high-definition video systems, simulation mannequins, and specialized training modules now carries elevated import duties, driving up the baseline investment for on-site workshops and cloud hosting providers and software vendors incorporated tariff-driven cost increases into subscription fees, affecting the economics of remote learning platforms. As hosting costs rose, some smaller providers faced difficult decisions: absorb the incremental expense, pass it on to attendees in the form of higher registration fees, or scale back investment in advanced features such as AI-driven analytics and real-time cost pressures have had a ripple effect on pricing structures across the board, leading to tighter budget allocations and more rigorous ROI evaluations. Sponsors are demanding clearer metrics on learner engagement and clinical impact before committing to funding new programs. Meanwhile, some forward-looking organizations are exploring strategic partnerships with domestic technology firms to mitigate tariff exposure and ensure continuity of Regional Dynamics for Targeted GrowthRegional dynamics underscore the need for geographically nuanced strategies. In the Americas, robust infrastructure and high digital adoption have accelerated the shift toward hybrid learning environments, yet disparities persist between urban centers and remote communities. Europe, the Middle East & Africa present a mosaic of regulatory landscapes and accreditation frameworks, requiring providers to navigate diverse compliance requirements and cultural preferences. In the Asia-Pacific region, rapid technological adoption coexists with variable access to digital resources, prompting innovative partnerships to extend reach into emerging markets. Across all regions, collaboration with local stakeholders and alignment with regional health priorities remain essential to driving adoption and ensuring Recommendations for Continuing Education StakeholdersTo thrive in this evolving ecosystem, industry leaders should adopt a multipronged approach. First, invest in scalable technology platforms that support both synchronous and asynchronous learning, ensuring seamless integration of virtual simulations, live streaming, and microlearning modules. Second, enhance content personalization by leveraging data analytics and AI to deliver competency-based curricula that adapt to individual learner profiles and specialty requirements. Third, establish transparent governance frameworks that meet the latest accreditation and conflict-of-interest standards, fostering trust among participants and pursue collaborative partnerships with domestic technology firms to hedge against tariff-driven cost increases, while exploring co-development agreements with regional stakeholders to customize offerings for local market needs. Prioritize outcome measurement by adopting robust evaluation methodologies that quantify clinical impact and return on educational investment, thereby strengthening the value proposition for sponsors. Finally, implement agile pricing models and flexible subscription plans that accommodate budget variability and incentivize long-term Topics Covered1. Preface2. Research Methodology2.1. Define: Research Objective2.2. Determine: Research Design2.3. Prepare: Research Instrument2.4. Collect: Data Source2.5. Analyze: Data Interpretation2.6. Formulate: Data Verification2.7. Publish: Research Report2.8. Repeat: Report Update3. Executive Summary4. Market Overview4.1. Introduction4.2. Market Sizing & Forecasting5. Market Dynamics6. Market Insights6.1. Porter's Five Forces Analysis6.2. PESTLE Analysis7. Cumulative Impact of United States Tariffs 20258. Continuing Medical Education Market, by Delivery Mode8.1. Introduction8.2. In-Person8.2.1. Conferences8.2.2. Seminars8.2.3. Symposia8.2.4. Workshops8.3. Online/Remote8.3.1. E-learning Courses8.3.2. Virtual Simulations8.3.3. Webinars9. Continuing Medical Education Market, by Specialty9.1. Introduction9.2. Cardiology9.3. Emergency Medicine9.4. Family Medicine9.5. Internal Medicine9.6. Neurology9.7. Obstetrics & Gynecology9.8. Oncology9.9. Pediatrics9.10. Psychiatry9.11. Surgery10. Continuing Medical Education Market, by Provider10.1. Introduction10.2. Academic Institutions10.2.1. Medical Schools10.2.2. Universities10.3. Commercial Organizations10.3.1. Medical Device Companies10.3.2. Pharmaceutical Companies10.4. Government Agencies10.4.1. Health Departments10.4.2. Regulatory Bodies10.5. Professional Societies & Associations10.5.1. Medical Associations10.5.2. Specialty Societies11. Continuing Medical Education Market, by Target Audience11.1. Introduction11.2. Dentists11.3. Nurses11.4. Physicians12. Americas Continuing Medical Education Market12.1. Introduction12.2. Argentina12.3. Brazil12.4. Canada12.5. Mexico12.6. United States13. Asia-Pacific Continuing Medical Education Market13.1. Introduction13.2. Australia13.3. China13.4. India13.5. Indonesia13.6. Japan13.7. Malaysia13.8. Philippines13.9. Singapore13.10. South Korea13.11. Taiwan13.12. Thailand13.13. Vietnam14. Europe, Middle East & Africa Continuing Medical Education Market14.1. Introduction14.2. Denmark14.3. Egypt14.4. Finland14.5. France14.6. Germany14.7. Israel14.8. Italy14.9. Netherlands14.10. Nigeria14.11. Norway14.12. Poland14.13. Qatar14.14. Russia14.15. Saudi Arabia14.16. South Africa14.17. Spain14.18. Sweden14.19. Switzerland14.20. Turkey14.21. United Arab Emirates14.22. United Kingdom15. Competitive Landscape15.1. Market Share Analysis, 202415.2. FPNV Positioning Matrix, 202415.3. Competitive Analysis15.3.1. 3M Company15.3.2. Abbott Laboratories15.3.3. B. Braun SE15.3.4. Baxter International Inc.15.3.5. BD (Becton, Dickinson and Company)15.3.6. Boston Scientific Corporation15.3.7. Cardinal Health, Inc.15.3.8. DJO Global, Inc.15.3.9. GE Healthcare15.3.10. Johnson & Johnson15.3.11. Koninklijke Philips N.V.15.3.12. McKesson Medical-Surgical Inc.15.3.13. Med Learning Group, LLC15.3.14. Medtronic PLC15.3.15. Oracle Corporation15.3.16. Pfizer Inc.15.3.17. Siemens Medical Solutions USA, Inc.15.3.18. Stryker Corporation15.3.19. Veradigm LLC15.3.20. WebMD LLC15.3.21. Zimmer Biomet Holdings, more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Cision Canada
27-05-2025
- Health
- Cision Canada
Dermalyser Receives CE Mark in Europe, Paving the Way for Life-Saving Melanoma Detection Tool
AI Medical Technology's smartphone-based software outperforms dermatologists in clinical trials; European commercial launch begins ahead of U.S. operations in 2027 STOCKHOLM, May 27, 2025 /CNW/ -- AI Medical Technology (AIM) has received CE mark approval for Dermalyser, its diagnostic decision support tool for melanoma detection. Designed for use on smartphones attached to a dermatoscope, the AI-powered tool has demonstrated superior performance compared to experienced dermatologists and is now cleared for use across Europe. Dermalyser is a stand-alone Medical Device Software (MDSW). Its clinical performance was validated through AI-DSMM, a real-world trial conducted at 36 primary care centres across Sweden. The study analysed 253 suspicious lesions across 228 patients, identifying 21 melanomas—11 of which were classed as thin invasive and 10 which were classified as in situ. Dermalyser achieved an AUROC of 0.960, with 95.2% sensitivity and 84.5% specificity. For invasive melanomas, it reached 100% sensitivity and 92.6% specificity, outperforming both expert dermatologists (AUROC 0.85) and general practitioners (AUROC 0.70). The device also surpassed competing melanoma diagnostic support tools. With CE certification granted, AIM is launching commercial operations throughout Europe in 2025, with an eye on a U.S. market entry via FDA 510(k) in 2027. "Naturally, we are delighted that Dermalyser is now cleared for the European market," said Christoffer Ekström, CEO and co-founder of AIM."Dermalyser is now cleared for the European market and we already have doctors waiting for using our tool—a clear testament to the trust in our solution. For me, this is the culmination of years of dedicated and hard work to improve the way skin cancer is diagnosed. I believe we will rapidly gain traction throughout Europe ahead of a US launch in 2027." Clinicians have welcomed the technology. Jennie Sandqvist, Chief Medical Officer at Sand Clinic in Stockholm, stated:"Integrating Dermalyser into our practice will assist us in detecting melanoma with exceptional precision, right at the point of care. This is not just a technological breakthrough, it's a shift in how we approach skin cancer diagnostics. For our patients, it means faster diagnosis, fewer unnecessary surgeries and potentially life-saving decisions made sooner." For more information, or to set up an interview or demo with AI Medical Technology, please contact: Christoffer Ekström AI Medical Technology CEO [email protected] +46 704 027101 Barnaby Pickering 59 North Communications [email protected] Richard Hayhurst 59 North Communications [email protected]
